Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

M P GoetzM ToiJ HuoberJ SohnO TrédanI H ParkM CamponeS-C ChenL M MansoS Paluch-ShimonO C FreedmanJ O'ShaughnessyX PivotS M TolaneyS A HurvitzA Llombart-CussacV AndréA SahaG van HalA ShahirH IwataS R D Johnston

Published in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)

Abemaciclib combined with an NSAI resulted in clinically meaningful improvement in median OS (intent-to-treat population: 13.1 months; subgroup with visceral disease: 14.9 months) in patients with HR+ HER2- ABC; however, statistical significance was not reached.

Keyphrases

insulin resistance
type diabetes
randomized controlled trial
metabolic syndrome
adipose tissue
phase iii
skeletal muscle
open label
childhood cancer